CTI™


Clinical Trial Insights
“Voices of Patients with Hands-On Experience”

Our Clinical Trial Insights (CTI™) product creates a deep understanding of the actual patient experience of your new product, while providing the evidence you need to differentiate your brand. This brings the voices of patients with hands-on experience to your studies. Ross Weaver has been interviewing patients who were in clinical trials since 2004.

Our CTI Plus™ product delivers the inside story from patients actively enrolled in your study, providing unparalleled real-time actionable information. With surveying conducted during the clinical trial, our breakthrough process enables you to hear from patients within your ongoing study.

Value of CTI™


CTI™ creates a deep understanding of the actual patient experience of your new product, while providing the evidence you need to differentiate your brand

PHASE 2

  • Competitive insights – determine where your product has valued benefits versus currently available brands.
  • Identify benefits not previously captured.
  • Identifies added claims that are technically feasible and valued based on PRO validated instruments.
  • Clarify the relevance and potential management of specific adverse events.
    Improve secondary packaging.

PHASE 3

  • Competitive insights – determine where your product has valued benefits versus currently available brands.
  • Improved launch communications.
  • Clarify the value of your product – onset and experience
…Plus so much more!

With CTI™

You understand the context of how your new product impacts lives


The lives of patients

The lives of their families

Data are translated from statistics to human beings

Internal teams are motivated

Provides an internal compass for all of the minute-to-minute decisions made by brand team members.

“Hearing and seeing this, it makes working nights and evenings worthwhile.”
Director, Global Brand Team, after a CTI™ presentation of results.

Examples


Example – Respiratory (Phase 2)


Conducted a study following Phase 3


  • Study was blinded.
  • Study was global.

Goals

  • Explore for any benefits beyond those already identified.
  • Enhance the secondary packaging.

Results

  • Patient experience was dramatic and vastly different than supported by the statistical findings.
  • Brand team threw out the positioning and started over, based on the patient experiences.
  • Client immediately contracted for the next CTI™, and institutionalizing CTI for all future products.

Example – Respiratory (Phase 3)


Conducted two studies for same product


  • One was for the initial indication and one for a follow-on indication.
  • Study was randomized and double-blinded.

Goals

  • Understand the timing of a benefit.
  • Understand the experience patients had with the new product as compared to experience they had in the past with marketed products.

Results

  • Clarified the timing of a benefit from the initial indication, which was then incorporated into the study design for the follow-on benefit.
  • Greatly helped with competitive intelligence and ad agency communications.

Example – Neurology (Phase 3)


Conducted a study during Phase 3


  • Study was blinded.

Goals

  • Explore for any benefits beyond those already identified.
  • Enhance the secondary packaging.

Results

  • Conducted interviews with the targeted clinical trial study subjects.
  • Client received the needed information. Were pleased to discover some patient-reported benefits.
  • Extensively revised secondary packaging, leading to positive comments at launch from physicians, nurses and patients.

Example- Cardiovascular(Phase2)


Conducted a study during Phase 2


  • Study was randomized and double-blinded.

Goals

  • Clarify the relevance and potential management of specific adverse events.

Results

  • Identified patients who took the study drug and had the adverse events.
  • Conducted interviews with the targeted clinical trial study subjects.
  • Client received the needed information. Helped the company decide to progress with the compound into Phase 3.

Example – Oncology (Phase 2)


Conducted a study during Phase 2


  • The product was a subcutaneous formation of a product on the market as an intravenous agent.
  • Study was not blinded.

Goals

  • Clarify the experience patients had who took the product during a Phase 2 study.

Results

  • Identified patients who took the study drug and had the adverse events.
  • Conducted interviews with the targeted clinical trial study subjects.
  • Client received the needed information.
  • Helped the company decide to not progress with the compound into Phase 3.

Example – Psychiatry (Phase 2)


Conducted a study during Phase 2


  • The product was entering a highly competitive marketplace.
  • Study was blinded.

Goals

  • Understand the experiences patients had with the new product as compared to experience they had in the past with marketed products.
  • Explore for any benefits beyond those already identified.

Results

  • Conducted interviews with the targeted clinical trial study subjects.
  • Client received the needed information, which clarified the benefits of the new product versus marketed products.
  • Helped the company as it sought partners for Phase 3.
Limitation
Interviews are conducted after the clinical trial is completed.